Navigation Links
SRI International to screen drugs that fight 2009 H1N1 influenza A
Date:5/13/2009

MENLO PARK, Calif. May 13, 2009 SRI International, an independent, nonprofit research and development organization, announced today that that it will screen a library of well-characterized drugs against the 2009 H1N1 influenza A virus, previously known as "swine flu." The work will be performed under a resource contract from the Division of Microbiology and Infectious Diseases (DMID) in the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

There is currently only one class of antiviral drugs, the neuraminidase inhibitors, available to treat this H1N1 infection. Identifying drugs from other chemical and mechanistic classes could provide more effective alternatives to current therapies and make it easier to provide sufficient quantities of drugs to a broad population, should the need arise. The development of new treatments may be expedited by screening drugs that have already well-characterized safety and toxicity profiles.

"SRI has expertise in screening new and approved drugs, including the development of novel uses for antibiotics and screening a library of licensed drugs to find compounds that show efficacy against biothreat agents. SRI appreciates the opportunity to apply its knowledge and skills to screening drugs against H1N1 flu and contributing to the overall understanding of the virus," said Amy Shurtleff, Ph.D., a senior virologist in SRI International's Biosciences Division, who will lead this screening program.

Although the number of new 2009 H1N1 influenza A virus cases appears to be slowing worldwide, viruses are unpredictable. In particular, it is not known how this new virus will behave when the seasonal flu season returns this fall and in subsequent years. Scientists are looking at the Southern Hemisphere now, where the flu season will begin soon, for any signs of changes in the H1N1 virus and how humans respond to the infection.

SRI has a long and successful history of drug discovery and development, which includes both screening of licensed drugs and finding and studying new chemical and biological therapeutics and vaccines. The virus will be handled in compliance with all guidelines prescribed by the Centers for Disease Control and Prevention (CDC) for handling this strain of influenza. SRI researchers will culture cell lines and study H1N1 virus growth under well-controlled conditions. Next, they will begin testing the first round of drugs. Assuming that some drugs show worthwhile efficacy and potency, SRI will help develop a plan for preclinical and clinical evaluation and regulatory approval.


'/>"/>

Contact: Dina Basin
dina.basin@sri.com
650-859-3845
SRI International
Source:Eurekalert

Related biology news :

1. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
2. ESMO International Symposium on Immunology
3. Conservation International and Toyota partner to protect Philippines rain forests
4. International team shows mercury concentrations in fish respond quickly to increased deposition
5. International team shows mercury concentrations in fish respond quickly to increased deposition
6. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
7. Youngstown, Ohio Police Award Mobile Data Contract to BIO-key(R) International
8. Clemson physicist addresses international forum on thermoelectric energy
9. US launch of international consultation for new responsible nanocode
10. International team of scientists warns of climate changes impact on global river flow
11. BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
(Date:3/9/2016)... 2016 Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> DERMALOG, the ...
(Date:3/8/2016)... N.C. , March 8, 2016   ... sensor technology, today announced it has secured $11M ... by GII Tech, a new venture fund being ... with additional participation from existing investors TDF Ventures ... the funds to continue its triple-digit growth and ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ALBANY, New York , April 29, 2016 ... market report published by Transparency Market Research "Separation ... Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... market was valued at US$ 10,665.5 Mn in ... CAGR of 6.8% from 2015 to 2023 to ...
(Date:4/29/2016)... ... 2016 , ... Intelligent Implant Systems announced today that the two-level components for ... the United States. These components expand the capabilities of the system and allow ... in October of 2015, the company has seen significant sales growth in 1Q 2016, ...
(Date:4/28/2016)... 28, 2016 Q BioMed ... Company,s CEO  was featured in an article he ... VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life ... biotechs to Big Pharmas. Their content is designed ...
(Date:4/28/2016)... NY (PRWEB) , ... April 28, 2016 , ... ... has made significant investments in recruiting top industry experts, and expanding its LATAM ... which provides industry-leading tools for clients to manage their clinical trial projects. , ...
Breaking Biology Technology: